![]() However, long-term survival patients were noted only in the allo-SCT group, and allo-SCT could exhibit clinical efficacy, particularly in the low-risk group. These findings suggest that ReASCT is more advantageous than allo-SCT in many patients with MM relapsing/progressing after the prior ASCT. We observed no significant advantages of allo-SCT over ReASCT in the low- and high-risk subgroups. Subgroup comparison revealed OS after ReASCT to be higher than that after allo-SCT in the intermediate-risk subgroup comprising the largest population (28.2% vs 21.5%, P <. ![]() We categorized patients into three risk subgroups based on their total points (0, 1-3, and 4-5 points), indicating the usefulness of this scoring system for prognosis prediction and treatment selection. We scored factor 2 as 1 point, factor 3 as 2 points, and factor 4 as 0, 1, or 2 points for more than 30, 9 to 30, or less than 9 months, respectively. Significant adverse factors for OS in all patients were (1) male sex, (2) less than partial response to SCT, (3) performance status of 2 to 4, and (4) short duration from the prior ASCT. Thus, in this retrospective study, we analyzed 526 patients with MM who underwent SCT for MM relapsing/progressing after the prior ASCT using the registry data of the Japan Society for Hematopoietic Cell Transplantation (2001-2015) and compared overall survival (OS) between allo-SCT (n = 192) and autologous stem cell retransplantation groups (ReASCT n = 334) based on risk factor points. 18 Department of Hematology/Respiratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Ishikawa, Japan.Īllogeneic stem cell transplantation (allo-SCT) offers a clinical option to young patients with multiple myeloma (MM) relapsing/progressing after autologous SCT (ASCT) however, this claim remains debatable.17 Department of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.16 Division of Hematology, Department of Medicine, Jichi Medical University, Tochigi, Japan.15 Department of Healthcare Administration, Nagoya University Graduate School of Medicine, Aichi, Japan.14 Japanese Data Center for Hematopoietic Cell Transplantation, Aichi, Japan.13 Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.12 Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.11 Department of Oncology/Hematology, Shimane University Hospital, Shimane, Japan.10 Department of Hematology, Tokyo Medical and Dental University, Tokyo, Japan. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |